Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are supported by the provided label excerpts (e.g., CDAD, seizures/CNS adverse experiences, hypersensitivity/anaphylaxis, carbapenem classification). However, several safety/ADR claims are treated as unsupported/absent without verification across the full label (only a subset of sections was provided), and multiple mechanistic/efficacy statements are marked unsupported due to missing excerpt text, preventing confirmation of on-label accuracy for the set of claims.
Category Scores
Accurate Statements
Ertapenem can cause Clostridioides difficile-associated diarrhea (CDAD).
Supported by Warnings and Precautions 5.4 (CDAD reported with use of nearly all antibacterial agents, including ertapenem).
CDAD from ertapenem can range in severity from mild diarrhea to fatal colitis.
Supported by 5.4 (may range in severity from mild diarrhea to fatal colitis).
Ertapenem can cause seizures and other CNS adverse experiences.
Supported by 5.2 (seizures and other CNS adverse experiences reported) and referenced Adverse Reactions 6.1.
Ertapenem is a carbapenem antibiotic.
Supported by Clinical Pharmacology 12.1 (ertapenem sodium is a carbapenem antibiotic).
Ertapenem can cause serious and occasionally fatal hypersensitivity (anaphylactic) reactions.
Supported by Warnings and Precautions 5.1 (serious and occasionally fatal hypersensitivity/anaphylactic reactions reported with beta-lactams including ertapenem therapy).
Unsupported Statements
Ertapenem can cause diarrhea (general diarrhea, not specifically CDAD).
Only CDAD-related diarrhea is supported in the provided excerpts (5.4). The label excerpt does not establish diarrhea as a general (non-CDAD-specific) adverse reaction.
Ertapenem can cause nausea.
No nausea adverse-reaction/precaution information is present in the provided label excerpts.
Ertapenem can cause vomiting.
No vomiting adverse-reaction/precaution information is present in the provided label excerpts.
Ertapenem can cause headache.
No headache adverse-reaction/precaution information is present in the provided label excerpts.
Ertapenem can cause rash.
The provided excerpts discuss hypersensitivity/anaphylaxis but do not specifically state rash.
Ertapenem can cause injection site reactions such as pain.
No injection site pain information is present in the provided label excerpts.
Ertapenem can cause injection site reactions such as redness.
No injection site redness information is present in the provided label excerpts.
Severe allergic reactions from ertapenem can involve difficulty breathing.
While hypersensitivity/anaphylaxis is discussed in 5.1, the provided excerpts do not explicitly list difficulty breathing.
Severe allergic reactions from ertapenem can involve swelling of the face.
While hypersensitivity/anaphylaxis is discussed in 5.1, the provided excerpts do not explicitly list facial swelling.
Severe allergic reactions from ertapenem can involve swelling of the throat.
While hypersensitivity/anaphylaxis is discussed in 5.1, the provided excerpts do not explicitly list throat swelling.
Ertapenem can cause severe skin reactions like blistering.
No blistering/peeling skin-reaction details are present in the provided label excerpts.
Ertapenem can cause severe skin reactions like peeling.
No blistering/peeling skin-reaction details are present in the provided label excerpts.
Ertapenem can cause neurological effects such as dizziness.
5.2 describes seizures and other CNS adverse experiences but does not explicitly state dizziness in the provided excerpts.
Ertapenem can cause neurological effects such as confusion.
5.2 describes seizures and other CNS adverse experiences but does not explicitly state confusion in the provided excerpts.
Ertapenem works by inhibiting bacterial cell wall synthesis.
Mechanism details beyond 'carbapenem antibiotic' are not present in the provided excerpts.
Inhibiting bacterial cell wall synthesis by ertapenem leads to bacterial death.
No such mechanistic/bactericidal statement is present in the provided excerpts.
Ertapenem is effective against a broad spectrum of gram-positive and gram-negative bacteria.
No antimicrobial spectrum-of-activity statement is present in the provided excerpts.
Contradictions
Low
AI Statement
No direct contradictions were identified against the provided label excerpts.
Label Reference
Important Omissions
Critical label safety areas (e.g., boxed warnings if any, full contraindications context, dosing/administration safety details, pregnancy and pediatric information, and laboratory monitoring details) were not assessed relative to the AI claims because only a subset of label sections was provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several adverse-reaction type claims (GI, neurologic symptoms, rash, injection-site reactions) are not confirmable from the provided label excerpts, and mechanistic/efficacy claims are also not supported by the excerpted sections. While no direct contradictions are present in the excerpts, incomplete label coverage limits confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are marked unsupported or not confirmable based on the provided label excerpts, and key label sections required to verify safety/administration details were not included in the available excerpt set for evaluation.
Suggested Improvement
Limit claims to those explicitly supported by the provided label excerpts (e.g., CDAD severity range, seizures/CNS adverse experiences, and hypersensitivity/anaphylaxis) or provide additional FDA label sections covering adverse reactions (6.1), detailed hypersensitivity symptoms, and full mechanistic/clinical pharmacology statements.